Showing results (291-300 of 335) with videos related to

Sort By:
Pageof 34
The Lancet. Oncology|January 27, 2018
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trialsSandra P D'Angelo, Michelle R Mahoney, Brian A Van Tine, et al.
Biorxiv : the Preprint Server for Biology|June 22, 2026
Post-translational modifications in the brain are critical contributors to Alzheimer's disease neuropathology and cognitive declineJulia B Libby, Emily R Mahoney, Ben Drucker, et al.
Brain Communications|April 15, 2022
Exploring common genetic contributors to neuroprotection from amyloid pathologyMabel Seto, Emily R Mahoney, Logan Dumitrescu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841George P Kim, Daniel J Sargent, Michelle R Mahoney, et al.
BMC Public Health|February 14, 2019
Breast Cancer knowledge, perceptions and practices in a rural Community in Coastal KenyaShahin Sayed, Anthony K Ngugi, Megan R Mahoney, et al.
Family Medicine and Community Health|April 12, 2024
Storylines of family medicine VIII: clinical approachesWilliam B Ventres, Leslie A Stone, Lauren E Gibson-Oliver, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 22, 2021
Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2Gina L Mazza, Molly M Petersen, Brenda Ginos, et al.
Investigational New Drugs|September 15, 2010
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinomaGeorge P Kim, Michelle R Mahoney, Daniel Szydlo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancerCarmen J Allegra, Allyson L Parr, Lester E Wold, et al.
Cancer|May 12, 2017
North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinomaRobert R McWilliams, Nathan R Foster, Michelle R Mahoney, et al.
Pageof 34